
After another six months had gone by, the virus was still undetectable in half of the combination patients, compared with just 5 percent in the interferon group.
Sales of interferon alpha-2b, which is used to treat viral diseases and cancer, pull in $600 million each year for Schering-Plough of Berlin.
Folkman knew, recent research had shown that interferon alpha, made by the body's immune system, could shut down overproduction of FGF.
That therapy eliminates the disease in only 10 percent to 20 percent of patients.
But researchers say that not all hepatitis C patients need Rebetron, which can have severe side effects including flulike symptoms, anemia, depression and suicidal behavior.
In a paper being published Tuesday in the journal Pediatrics, Folkman, Kaban, and colleagues describe how the tumor was finally beaten with a yearlong regimen of a drug, interferon alfa-2a, that knocked out the tumor's ability to recruit new blood vessels.
Food and Drug Administration approved a new approach, a combination of interferon and ribavirin.
The disease, spread mainly by dirty needles and exposure to infected blood, is the leading reason for liver transplants.
The disease is the leading reason for liver transplantation.
At least 2.7 million Americans carry the hepatitis C virus, making it the most common blood-borne infection in the United States, according to a study in today's New England Journal of Medicine.

